Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This prospective study will examine eosinophils in various biological materials to compare the detection in those materials and ascertain the prognostic and predictive role of eosinophils in untreated non-small cell lung cancer patient.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eosinophil detection | Experimental | Eosinophils will be measured in blood, sputum, bronchoalveolar lavage if available and biopsies. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| induced sputum | Diagnostic Test | After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline. |
| Measure | Description | Time Frame |
|---|---|---|
| Detection of eosinophils in untreated non-small cell lung cancer patients | Concentration of eosinophils will be used in various bodily materials as described above. | Baseline (pre-treatment) |
| Measure | Description | Time Frame |
|---|---|---|
| Prognostic and predictive value of eosinophils in non-small cell lung cancer patients | Baseline (pre-treatment) and, if immunotherapy, after 3 months of treatment |
Not provided
Inclusion Criteria:
o All stages of NSCLC
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anne Sibille, MD | Contact | +3243237452 | anne.sibille@chuliege.be | |
| Aurore Cue Alvarez | Contact | +3243235539 | aurore.cuealvarez@chuliege.be |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Liège | Recruiting | Liège | 4000 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| lung biopsy | Diagnostic Test | As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site. |
|
| bronchoalveolar lavage | Diagnostic Test | When available, the remaining material from a patient's bronchoalveolar lavage will be collected. |
|
| blood draw | Diagnostic Test | As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected. |
|
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |